MAP2K7 and neoplasm: Sorafenib is a multikinase inhibitor that represses tumor‐cell proliferation and angiogenesis and promotes tumor‐cell apoptosis by inhibiting the Raf/MEK/ERK signaling pathway and VEGF receptor tyrosine kinase.